Skip to main content

The CLIO consortium: Optimization of Cerenkov Luminescence Imaging for Image-Guided Cancer Surgery

Objective

Cancer is the second largest cause of death and morbidity in Europe, with more than 3 million new cases diagnosed each year. The most effective treatment strategy for most forms of cancer is early detection followed by surgery. However, cancers frequently recur following surgery. For example, nearly 1 in 4 breast cancer patients will see their tumour recur after surgery. The consequences of cancer recurrence include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic and functional outcomes, emotional distress, and financial cost. The financial costs are staggering. Europe spends €125 billion annually on cancer care, approximately 5% of which is managing post-surgical recurrence.

Tumours recur after surgery primarily due to incomplete excision of the tumour or inadequate clearance of surgical margins. Tumours fail to be completely excised because the surgeon only has the visual appearance of the tumor and palpation to differentiate malignant from benign tissue. Consequently, there is an urgent clinical and market need for improved tools to detect cancerous tissue during surgery.

Real-time imaging during surgery would enable the surgeon to more accurately resect tumors and thereby reduce the likelihood of post-surgical recurrence. Cerenkov luminescence imaging (CLI) is a ground-breaking imaging modality that can provide real-time molecular imaging during surgery

The CLIO consortium will develop a Cerenkov luminescence imaging device and a handheld intraoperative beta particle imaging device for image-guided surgery as well as imaging services for the pharmaceutical and medical device sectors. The imaging services will enable pharmaceutical and medical device clients to improve the efficacy evaluation of pharmaceutical and surgical device products. The consortium contains world-leading expertise in medical device product development, clinical and preclinical imaging, oncologic surgery, and surgical device evaluation.

Call for proposal

FP7-SME-2013
See other projects for this call

Coordinator

CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT
Address
Baross Utca 91 95
1047 Budapest
Hungary
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 614 521,90
Administrative Contact
Mariann Semjeni (Ms.)

Participants (6)

ORSZAGOS FREDERIC JOLIOT-CURIE SUGARBIOLOGIAI ES SUGAREGESZSEGUGYI KUTATO INTEZET

Participation ended

Hungary
Address
Anna U 5
1221 Budapest
Activity type
Other
Administrative Contact
Lajos Balogh (Dr.)
ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH
Germany
EU contribution
€ 108 583,97
Address
Blasewitzer Str 78-80
01307 Dresden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andreas Kluge (Dr.)
LIGHTPOINT MEDICAL LTD
United Kingdom
EU contribution
€ 609 894,12
Address
Misbourne Works Waterside
HP5 1PE Chesham
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
David Tuch (Dr.)
SAGENTIA LIMITED
United Kingdom
Address
Harston Mill
CB22 7GG Harston, Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sarah Cole
SEMMELWEIS EGYETEM
Hungary
Address
Ulloi Utca 26
1085 Budapest
Activity type
Higher or Secondary Education Establishments
Administrative Contact
ákos Balázs (Dr.)
NEMZETI NEPEGESZSEGUGYI KOZPONT
Hungary
Address
Albert Florian Ut 2-6
1097 Budapest
Activity type
Research Organisations
Administrative Contact
Lajos Balogh (Dr.)